Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-06-19
2007-06-19
Rao, Deepak (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S259400, C514S259410, C544S279000, C544S280000, C544S281000
Reexamination Certificate
active
10504677
ABSTRACT:
The invention relates to a pyrimidone derivative represented by formula (I) or a salt thereof wherein: (I) X represents two hydrogen atoms, a sulphur atom, an oxygen atom or a C1-2alkyl group and a hydrogen atom; Y represents a bond, an ethenylene group, an ethynylene group or a methylene group optionally substituted; R1 represents a 2, 3 or 4-pyridine ring or a 2, 4 or 5-pyrimidine ring optionally substituted; R2 represents a heterocyclic bicyclic rings, having 1–4 heteroatoms selected from an oxygen atom, a sulfur atom and a nitrogen atom and having 5–9 carbon atoms, of formula (II) R3 represents a hydrogen atom, a C1-6alkyl group, a hydroxy group, a C1-4alkoxy group or a halogen atom; R4 represents a hydrogen atom, a C1-6alkyl group, a C1-4alkoxy group or a halogen atom. The invention relates also to a medicament comprising the said derivative or a salt thereof as an active ingredient which is used for preventive and/or therapeutic treatment of a neurodegenerative disease caused by abnormal activity of GSK3β or GSK3β and cdk5/p25, such as Alzheimer disease
REFERENCES:
patent: WO00/18758 (2000-04-01), None
patent: WO02/18386 (2002-03-01), None
Leclerc, et al. (“Indirubins Inhibit Glycogen Synthase Kinase-3β and CDK5/P25, Two Protein Kinases Involved in Abnormal Tau Phosphorylation in Alzheimer's Disease,” The Journal of Biological Chemistry, 276, No. 1, Jan. 2, 2001, pp. 251-260).
Bhat, et al. (“Glycogen Synthase Kinase 3: A Drug Target for CNS Therapies,” Journal of Neurochemistry, 2004, 89, 1313-1317).
Souillac, et al., Characterization of Delivery Systems, Differential Scanning Calorimetry, pp. 217-221 (in Encyclopedia of Controlled Drug Delivery, 1999, John Wiley & Sons, pp. 212-227).
Wagman, et al., Discovery and Development of GSK3 Inhibitors for the Treatment of Type 2 Diabetes, Current Pharmaceutical Design, 2004, 10, 1105-1137.
Disorders Index of the National Institute of Neurological Disorders and Stroke, Oct. 2006 http://www.ninds.nih.gov/disorders/disorder—index.htm?css=print.
Harwood, (PubMed abstract of Curr. Mol. Med., Aug. 2003; 3(5): 472-82).
Lochead Alistair
Nedelec Alain
Saady Mourad
Yaiche Philippe
Gupta Balaram
Jaisle Cecilia
Mitsubishi Pharma Corporation
Rao Deepak
Sanofi-Aventis
LandOfFree
Heteroaryl substituted 2-pyridinyl and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Heteroaryl substituted 2-pyridinyl and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Heteroaryl substituted 2-pyridinyl and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3849466